SCOPUS 정보 검색 플랫폼

Archives of Physical Medicine and Rehabilitation

Volumn 88, Issue 3 SUPPL.1, 2007, Pages

Industrial Medicine and Acute Musculoskeletal Rehabilitation. 2. Medications for the Treatment of Acute Musculoskeletal Pain

(6) Sullivan, William J a Panagos, Andre b Foye, Patrick M c Sable, Aaron W d Irwin, Robert W e Zuhosky, Joseph P f

a UNIVERSITY OF COLORADO (United States)

b WEILL CORNELL MEDICAL CENTER (United States)

c RUTGERS NEW JERSEY MEDICAL SCHOOL (United States)

d St John's Macomb Hospital (United States)

e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE (United States)

f CAROLINAS MEDICAL CENTER (United States)

Author keywords

Administration, topical; Analgesics; Anti inflammatory agents; Muscle relaxants, central; Rehabilitation

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BROMFENAC; CARISOPRODOL; CELECOXIB; CENTRAL DEPRESSANT AGENT; CHLORZOXAZONE; CYCLOBENZAPRINE; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; DICLOFENAC POTASSIUM; KETOROLAC; LIDOCAINE; LIMBREL; MELOXICAM; METAXALONE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORPHENADRINE; ORPHENADRINE CITRATE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PLACEBO; ROFECOXIB; SPASMOLYTIC AGENT; TIZANIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; ULTRAM ER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; EDUCATION PROGRAM; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INDUSTRIAL MEDICINE; LEARNING; LETHARGY; MEDICAL EDUCATION; MUSCULOSKELETAL PAIN; OCCUPATIONAL ACCIDENT; PHYSICAL MEDICINE; REHABILITATION MEDICINE; SEDATION; SIDE EFFECT; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ADMINISTRATION, TOPICAL; ANALGESICS, NON-NARCOTIC; ANKLE INJURIES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSAICIN; HUMANS; MUSCLE RELAXANTS, CENTRAL; OCCUPATIONAL DISEASES; TENNIS ELBOW; WHIPLASH INJURIES;

EID: 33847160254 PISSN: 00039993 EISSN: None Source Type: Journal
DOI: 10.1016/j.apmr.2006.12.009 Document Type: Article

Times cited : (12)

References (15)

1
- 33847120897
- note
- Key reference.

2
- 24944562697
- Skeletal muscle relaxants and associated medications for nonspecific acute back pain
- Reeves R.R., Algood T.L., and Wise P.M. Skeletal muscle relaxants and associated medications for nonspecific acute back pain. P&T 30 (2005) 518-524
- (2005) P&T , vol.30 , pp. 518-524
- Reeves, R.R.¹ Algood, T.L.² Wise, P.M.³

3
- 0034582856
- A review of three commonly prescribed skeletal muscle relaxants
- *
- *
- (2000) J Back Musculoskeletal Rehabil , vol.15 , pp. 63-66
- Harden, R.N.¹ Argoff, C.²

4
- 0034916120
- Cyclobenzaprine and back pain: a meta-analysis
- Browning R., Jackson J.L., and O'Malley P.G. Cyclobenzaprine and back pain: a meta-analysis. Arch Int Med 161 (2001) 1613-1620
- (2001) Arch Int Med , vol.161 , pp. 1613-1620
- Browning, R.¹ Jackson, J.L.² O'Malley, P.G.³

5
- 0025348916
- Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm
- Borenstein D.G., Lacks S., and Wiesel S.W. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther 12 (1990) 125-131
- (1990) Clin Ther , vol.12 , pp. 125-131
- Borenstein, D.G.¹ Lacks, S.² Wiesel, S.W.³

6
- 15944386050
- FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs
- Kuehn B.M. FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA 293 (2005) 1571-1572
- (2005) JAMA , vol.293 , pp. 1571-1572
- Kuehn, B.M.¹

7
- 27844530850
- US Food and Drug Administration Available at: http://www.fda.gov/cder/drug/infopage/COX2/default.htm. Accessed June 12
- US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (2006). http://www.fda.gov/cder/drug/infopage/COX2/default.htm Available at: http://www.fda.gov/cder/drug/infopage/COX2/default.htm. Accessed June 12
- (2006) COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs)

8
- 0142094513
- Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
- Oviedo J.A., and Wolfe M.M. Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?. Rheum Dis Clin N Am 29 (2003) 769-788
- (2003) Rheum Dis Clin N Am , vol.29 , pp. 769-788
- Oviedo, J.A.¹ Wolfe, M.M.²

9
- 0031685519
- Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum in: Br J Rheumatol 1998;37:1142]
- Hawkey C., Kahan A., Steinbruck K., et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum in: Br J Rheumatol 1998;37:1142]. Br J Rheumatol 37 (1998) 937-945
- (1998) Br J Rheumatol , vol.37 , pp. 937-945
- Hawkey, C.¹ Kahan, A.² Steinbruck, K.³

10
- 7644232150
- Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis
- Weideman R.A., Kelly K.C., Kazi S., et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology 127 (2004) 1322-1328
- (2004) Gastroenterology , vol.127 , pp. 1322-1328
- Weideman, R.A.¹ Kelly, K.C.² Kazi, S.³

11
- 0037325473
- Review article: NSAIDs, gastroprotections and cyclo-oxygenase-II-selective inhibitors
- *
- *
- (2003) Aliment Pharmacol Ther , vol.17 , pp. 321-332
- Micklewright, R.¹ Lane, S.² Linley, W.³ McQuade, C.⁴ Thompson, F.⁵ Maskrey, N.⁶

12
- 14644394914
- Oral analgesics for acute nonspecific pain
- *
- *
- (2005) Am Fam Physician , vol.71 , pp. 913-918
- Sachs, C.J.¹

13
- 0037373297
- Topical and peripherally acting analgesics
- Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev 55 (2003) 1-20
- (2003) Pharmacol Rev , vol.55 , pp. 1-20
- Sawynok, J.¹

14
- 85042806500
- The 5% lidocaine patch reduces pain intensity in professional athletes with sports injury pain without significant systemic effects or cognitive and performance impairment [abstract]
- Benoist J.L., and Gammaitoni A.R. The 5% lidocaine patch reduces pain intensity in professional athletes with sports injury pain without significant systemic effects or cognitive and performance impairment [abstract]. Arch Phys Med Rehabil 86 (2005) E34
- (2005) Arch Phys Med Rehabil , vol.86
- Benoist, J.L.¹ Gammaitoni, A.R.²

15
- 2142716021
- Analgesics for acute pain: meeting the United States Food and Drug Administration's requirements for proof of efficacy
- Ridgway D. Analgesics for acute pain: meeting the United States Food and Drug Administration's requirements for proof of efficacy. Clin J Pain 20 (2004) 123-132
- (2004) Clin J Pain , vol.20 , pp. 123-132
- Ridgway, D.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.